Retinal detachment rates following acute retinal necrosis are unaffected by early treatment with antivirals, vitrectomyOctober 2nd 2022
The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.
Utilising AAO cornea preferred practice patterns for corneal oedema, opacifications, ectasia and bacterial keratitisOctober 1st 2022
David Hutton discusses the AAO 2022 talk, "Corneal Oedema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with presenter Dr Francis S. Mah.
Comparing dry eye disease in adult and paediatric populations via the IRIS RegistryOctober 1st 2022
Almost 5 million patients in the IRIS Registry had received at least one diagnosis of DED between 2013 and 2019; of those, 203,171 were children under 18 years of age and 4,592,808 were adults.
Higher incidence of new strabismus in paediatric patients following tube shunt surgerySeptember 30th 2022
13% of pediatric patients had new-onset strabismus after a tube shunt procedure; in contrast, 0% of adults had new-onset strabismus after tube shunt surgery (at 6 months or at last follow-up).
Corneal cross-linking and epithelial management: four pearls for successFebruary 4th 2022
Dr Preeya Gupta walks through her four pearls for successful corneal collagen cross-linking, including handling patient expectations, managing the epithelial cells and preventing infectious keratitis.
Updates on brolucizumab for treatment of wet AMD and DMODecember 23rd 2021
Dr Jill Hopkins discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular oedema.
Shedding light on antibiotic resistance in ophthalmology with ARMOR study dataDecember 20th 2021
At the 2021 American Academy of Ophthalmology annual meeting, Dr Penny Asbell discussed data from the ARMOR study and its effects on treating ophthalmic infections, such as endophthalmitis.